Peripheral blood inflammatory score using a cytokine multiplex assay predicts clinical outcomes in patients treated with atezolizumab-bevacizumab for unresectable HCC
These results suggest that a peripheral blood marker-based scoring system can significantly predict clinical outcomes in patients with AB-treated HCC. This non-invasive biomarker is expected to be a potential predictive and prognostic factor for AB treatment.
Authors
- Ji Won Han (ORCID: https://orcid.org/0000-0003-1456-1450)
- Pil Soo Sung (ORCID: https://orcid.org/0000-0002-5780-9607)
- Jeong Won Jang (ORCID: https://orcid.org/0000-0003-3255-8474)
- Soon Kyu Lee (ORCID: https://orcid.org/0000-0003-1865-8225)
- Young Chul Yoon (ORCID: https://orcid.org/0000-0002-5341-2370)
- Jung Hyun Kwon (ORCID: https://orcid.org/0000-0002-5484-5864)
- Jae Jun Lee (ORCID: https://orcid.org/0000-0002-5418-500X)
- Keungmo Yang (ORCID: https://orcid.org/0009-0005-0922-6588)
- Jong Young Choi
- Soon Woo Nam
- Hee Sun Cho (ORCID: https://orcid.org/0009-0001-6587-5081)
Institutions
- St. Mary's Hospital (US)
- The Catholic University of Korea Incheon St. Mary's Hospital (KR)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-06-11
- DOI
- https://doi.org/10.3389/fimmu.2025.1578422
- Citations
- 4
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 4.18
Funders
- Korea Health Industry Development Institute